This study evaluates the anti-tumor efficacy of CCX559, an orally administered small molecule inhibitor of PD-L1. CCX559 effectively inhibits PD-L1 interactions, enhances T-cell activation, and demonstrates significant tumor growth inhibition in human PD-L1-expressing murine tumor models.
CCX559 selectively inhibits human PD-L1 binding to PD-1 and CD80, enhances T-cell receptor signaling and activation, induces PD-L1 dimerization and internalization, and demonstrates significant tumor growth inhibition in MC38-hPD-L1 tumor-bearing mice.
MC38-hPD-L1 tumor model developed by genOway, in which the murine MC38 colon carcinoma cell line was engineered to express human PD-L1, enabling the assessment of human-specific PD-L1 inhibitors like CCX559 in an immunocompetent setting.
Cancer immunotherapy, PD-L1 inhibition, T-cell activation, Tumor growth inhibition
MC38-hPD-L1 tumor model, Human PD-L1 expression, In vivo efficacy assessment, T-cell activation assays
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
